Skip to main content


Nexeon MedSystems Belgium is developing an innovative and non-invasive neurostimulation product for the treatment management of patients suffering from atrial fibrillation (AF). AF is the most common arrhythmia diagnosed in clinical practice and is predicted to affect 17.9 million people in Europe by 2060 and 6–12 million people in the USA by 2050.  ...
Read More


Development of a neuronal technology to detect and treat attention deficit hyperactivity disorder (ADHD) NeuroAtt aims to design novel electrophysiological diagnostic tools (EDT) and brain wave trainers (BWT) in attention deficit hyperactivity disorder (ADHD). It includes the development of methods to analyse multi-channel EEG recordings during sensorimotor and cognitive tasks...
Read More